The IP protection for the company’s drug candidates rugocrixan and fosrugocrixan relies on two main components – patent protection and market exclusivity through data protection. IP development is an integrated component of the Novakand Pharma’s research and development.
The IP protection for rugocrixan and fosrugocrixan is based on five patent families and basis for data exclusivity according to the table below:
| Type of IP | Territories | Term | Status |
|---|---|---|---|
| Chemical structure¹ | USA, Germany, France, Italy, UK, Japan and China | 2027 | Granted |
| Manufacturing process² | USA, Europe, Japan, Korea, China and certain other selected territories | 2039 | Granted in USA, Japan, Korea, China and certain other territories |
| Product³ | USA | 2039 | Granted |
| New clinical use⁴ | USA, Europe, Japan, Korea, China and certain other selected territories | 2044 | Ongoing review |
| Data exclusivity | USA and Europe | 5-10 years from market approval | Application to be submitted after market approval |
Source: Novakand Pharma
1) Two patent families
2) One patent family covers the manufacturing processes for both KAND145 and KAND567
3) Divisional application from manufacturing process
4) STEMI and certain other indications
| Type of IP | Territories | Term | Status |
|---|---|---|---|
| Chemical structure | USA, Europe, Japan, Korea, China and certain other selected territories | 2039 | Granted in USA, Japan, Korea, China and certain other territories |
| Manufacturing process² | USA, Europe, Japan, Korea, China and certain other selected territories | 2039 | Granted in USA, Japan, Korea, China and certain other territories |
| New clinical use⁴ | USA, Europe, Japan, Korea, China and certain other selected territories | 2044 | Ongoing review |
| Data exclusivity | USA and Europe | 5-10 years from market approval | Application to be submitted after market approval |
Source: Novakand Pharma
1) Two patent families
2) One patent family covers the manufacturing processes for both KAND145 and KAND567
3) Divisional application from manufacturing process
4) STEMI and certain other indications